摘要
目的探讨艾地苯醌对慢性精神分裂症患者认知功能障碍的疗效及安全性。方法将104例男性慢性精神分裂症患者随机分为研究组和对照组各52例,研究组在服用抗精神病药利培酮的基础上加用艾地苯醌30mg,3次/d,对照组在服用抗精神病药利培酮基础上加用安慰剂,进行12周的研究。分别于入组时、第2周末、第4周末、第8周末和第12周末采用中文版可重复神经心理状态测验(repeatable battery for neuropsychological status,RBANS)评定患者的认知功能,采用阳性阴性症状量表(positive and negative syndrome scale,PANSS)和治疗不良反应量表(treatment emergent symptom scale,TESS)评定疗效及不良反应。结果研究组病情控制的有效率更为理想;2组治疗后RBANS评分逐渐升高、PANSS评分逐渐下降,但研究组升高和降低的幅度更大,2组RBANS评分和PANSS评分组间、时点间、组间·时点间交互作用差异均有统计学意义(P<0.05)。2组不良反应发生率差异均无统计学意义(P>0.05)。结论艾地苯醌治疗慢性精神分裂症患者认知功能障碍是有效、安全的,可以应用于临床中。
Objective To investigate the efficacy and safety of idebenone on chronic schizophrenia patients with cognitive dysfunction. Methods One hundred and four cases of male chronic hospital schizophrenia were randomly divided into study group（ n = 52） and control group（ n = 52） for 12 weeks.Study group was treated with antipsychotics and idebenone, and control group was treated with antipsychotics and placebo. Before and 2,4,8,12 weeks after treatment,repeatable battery for neuropsychological status（ RBANS） was used to evaluate the cognitive function,and positive and negative syndrome scale（ PANSS） and treatment emergent symptom scale（ TESS） were used to evaluate the clinical efficacy and side effects respectively. Results Patients in the study group were more effective in the control of the disease（ P〈0. 05）. After treatment RBANS scores in the 2 groups of patients were gradually increased,PANSS scores were decreased gradually. The differences of RBANS score and PANSS score of the 2 groups have statistical significance in the groups,in the time point,in the interaction of group and the point（ P〈0. 05）. There was no significant difference in adverse reaction rates between the 2 groups（ P〉0. 05）. Conclusion Idebenone on cognition in patients with chronic mental disorders is safe and effective,and can be used in clinic.
出处
《河北医科大学学报》
CAS
2016年第11期1253-1256,共4页
Journal of Hebei Medical University
